| Pharmaceutical Information |
| Drug Name |
Bempedoic acid |
| Drug ID |
BADD_D02533 |
| Description |
High levels of LDL cholesterol (LDL-C) are a major risk factor for cardiovascular events. Caused by genetic mutations or lifestyle factors, hypercholesterolemia can significantly reduce quality of life and increase the risk of mortality from cardiovascular disease.[L12153] About 1 in 4 patients, or 15 million Americans with elevated LDL-C, are insufficiently managed with maximally tolerated statin therapy alone, requiring additional treatment for hypercholesterolemia.[L12180]
Bempedoic acid is first-in-class adenosine triphosphate-citrate lyase (ACL) inhibitor used once a day for reducing LDL cholesterol levels in statin-refractory patients.[L12144,L12147] It was developed by Esperion Therapeutics Inc. and approved by the FDA on February 21, 2020. A combination product of bempedoic acid and [ezetimibe] was approved on February 26, 2020 for increased control of LDL cholesterol levels in patients experiencing refractory elevations despite previous statin treatment.[L12144,L12150] |
| Indications and Usage |
Bempedoic acid is indicated as an adjunct to diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia or existing atherosclerotic cardiovascular disease that warrants additional lowering of LDL-C.[L12144]
The combination of bempedoic and ezetimibe is also indicated with diet management and maximally tolerated statin therapy to treat elevated LDL-C levels in adults with heterozygous familial hypercholesterolemia or existing atherosclerotic cardiovascular disease who require further lowering of LDL-C.[L12150] |
| Marketing Status |
approved; investigational |
| ATC Code |
C10AX15 |
| DrugBank ID |
DB11936
|
| KEGG ID |
D10691
|
| MeSH ID |
C581236
|
| PubChem ID |
10472693
|
| TTD Drug ID |
D0D9NY
|
| NDC Product Code |
72426-118; 12869-170; 42765-039; 70447-0003; 82608-002; 81666-002; 59285-041; 71796-049 |
| UNII |
1EJ6Z6Q368
|
| Synonyms |
8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid | bempedoic acid | nilemdo | nexletol | ETC-1002 | ESP55016 | ESP-55016 |
|
| Chemical Information |
| Molecular Formula |
C19H36O5 |
| CAS Registry Number |
738606-46-7 |
| SMILES |
CC(C)(CCCCCC(CCCCCC(C)(C)C(=O)O)O)C(=O)O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
